Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 3837-3844

  Vesselle, Hubert ^a   Schmidt, Rodney A ^b   Pugsley, Jeffrey M ^a   Li, Melissa ^b   Kohlmyer, Steve G ^a   Vallieres, Eric ^b   Wood, Douglas E ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL DAMAGE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; DRUG UPTAKE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY; TUMOR VOLUME; WHOLE BODY TOMOGRAPHY;

DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; PROGNOSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033754806     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Cancer statistics, 1999
2. Revisions in the international system for staging lung cancer
3. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small cell lung carcinomas: Are these carcinomas candidates for video-assisted lobectomy?
4. Sites of recurrence in resected stage I non-small cell lung cancer. A guide for future studies
5. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer
6. Stage I non-small cell lung cancer: A multivariate analysis of treatment methods and patterns of recurrence
7. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1N0M0 non-small cell lung cancer
8. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter
9. DNA analysis by flow cytometry in non-small cell lung cancer: Relationship to epidermal growth factor, histology, tumour stage and survival
10. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer
11. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small cell lung cancer
12. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma
13. Ki-67 immunostaining and survival in operable lung cancer
14. Prognostic significance of Ki-67 labeling in resected non-small cell lung cancer
15. Prognostic significance of the proliferation index in surgically-resected non-small cell lung cancer
16. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression
17. Value of Ki-67 immunostaining in preoperative biopsies of carcinomas of the lung
18. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients
19. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer
20. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer
21. Relation of neovascularization to metastasis of non-small cell lung cancer
22. Fluorodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors
23. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry
24. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity
25. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors
26. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose
27. Prediction of survival in glioma patients by means of positron emission tomography
28. 18]fluoro-deoxyglucose in brain tumors. A powerful diagnostic and prognostic tool
29. Positron emission tomography in patients with glioma: A predictor of prognosis
30. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis
31. FDG-PET for predicting the prognosis of malignant lymphoma
32. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma
33. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas
34. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[F-18]-D-glucose
35. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma
36. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography
37. Tumor doubling time and prognosis in lung cancer patients: Evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group
38. Tumor doubling time and prognostic assessment of patients with primary lung cancer
39. Prognostic significance of flow cytometry in lung cancer. A 5-year study
40. Comparison of recovery coefficients for PET based on maximum and average ROI pixel values
41. Regional 2-[F-18]fluorodeoxyglucose uptake varies in normal lung
42. A formula to estimate the approximate surface area if height and weight be known
43. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope
44. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data
45. Tumor metabolic rates in sarcoma using FDG PET
46. Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET
47. [F-18]Fluorodeoxyglucose uptake in tumors: Kinetic vs. steady-state methods with reference to plasma insulin
48. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
49. The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification?
50. SUV: Standard uptake or silly useless value?
51. FDG uptake of non-small cell lung cancer: Correlation with cell proliferation and cellular density
52. Fluorine-18-FDG imaging is negative in bronchioloalveolar lung carcinoma
53. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinoma
54. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma
55. Facilitative glucose transporters
56. FDG uptake, tumor characteristics and response to therapy: A review
57. Overexpression of Glut1 and Glut3 in stage I non-small cell lung carcinoma is associated with poor survival
58. Glut1 expression in human breast carcinoma: Correlation with known prognostic markers